Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06626087 | A Prototype AI Algorithm Versus Liver Imaging Reporting and Data System (LI-RADS) Criteria in Diagnosing HCC on CT(Hepatocellular) | completed | N/A | 300 | The University of Hong KongOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT01334073 | Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors(EVAX) | completed | Phase 1 | 19 | University Hospital, BordeauxOTHER | 1 |
| May 14, 2026 |
| clinicaltrials |
| NCT03033446 | Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma | completed | Phase 2 | 40 | National Cancer Centre, SingaporeOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT02689427 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT02761889 | Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer | completed | N/A | 444 | Fundacao ChampalimaudOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03415854 | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)(NABPLAGEMD) | completed | Phase 2 | 34 | HonorHealth Research InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT06881446 | Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without TACE for Advanced HCC With Vascular Invasions | completed | — | 2,651 | Zhongda HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03851237 | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy | completed | Phase 1 | 69 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04987203 | Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma | completed | Phase 3 | 343 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | May 8, 2026 | clinicaltrials |
| NCT03229083 | Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma | completed | N/A | 21 | University of RochesterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02535533 | SLM + Axitinib for Clear Cell RCC | completed | Phase 1 / Phase 2 | 45 | Mohammed MilhemOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | completed | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT04358185 | Itacitinib in Advanced Hepatocellular Carcinoma(JAKaL) | completed | Phase 1 | 19 | Imperial College LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | completed | Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04118114 | Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors | completed | Phase 2 | 14 | National Cancer Centre, SingaporeOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06261047 | Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer | completed | — | 36 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT02664935 | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | completed | Phase 2 | 423 | University of BirminghamOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02366286 | Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants | completed | — | 892 | Mayo ClinicOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06059014 | Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer(PRadR) | completed | Phase 1 / Phase 2 | 6 | Centre Leon BerardOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05625893 | Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion | completed | Phase 2 | 63 | Samsung Medical CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03138720 | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer | completed | Phase 2 | 40 | HonorHealth Research InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06138496 | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01899261 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | N/A | 20 | Montefiore Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05332496 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC(CHANCE2202) | completed | — | 941 | Zhongda HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05332821 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC(CHANCE2201) | completed | — | 1,244 | Zhongda HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06233981 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis | completed | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04085276 | Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment(TORCHLIGHT) | completed | Phase 3 | 531 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04028245 | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma(SPARC-1) | completed | Early Phase 1 | 17 | Columbia UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05247164 | EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients(EUPhORIC) | completed | N/A | 23 | IRCCS San RaffaeleOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02606396 | Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer | completed | N/A | 15 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529613 | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low) | completed | Phase 1 / Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02705859 | Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)(Panther) | completed | Phase 1 | 26 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02771405 | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC(FRI-STC) | completed | Phase 3 | 150 | National Hepatology & Tropical Medicine Research InstituteOTHER_GOV | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02928978 | Ruxolitinib for Premalignant Breast Disease(TBCRC042) | completed | Phase 2 | 84 | Julie NangiaOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04416646 | Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma(ZEBRA) | completed | — | 100 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05263362 | An Integrated Optimization of Surgery and Radiotherapy Techniques to Improve Cosmetic Outcome and Quality of Life in Breast Conserving Therapy for Breast Cancer Patients (STARLINGS Study)(STARLINGS) | completed | — | 775 | Erasmus Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06086002 | Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular Carcinoma | completed | N/A | 20 | Seoul National University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07192172 | Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes(ERFA) | completed | N/A | 100 | Seoul National University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04241367 | Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy | completed | — | 420 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02595905 | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | completed | Phase 2 | 344 | National Cancer Institute (NCI)NIH | 2 | Apr 8, 2026 | clinicaltrials |
| NCT06020651 | Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside(VICKI) | completed | N/A | 39 | Institut Mutualiste MontsourisOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04132505 | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | completed | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials